Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing.

Porras C, Hildesheim A, González P, Schiffman M, Rodríguez AC, Wacholder S, Jiménez S, Quint W, Guillen D, Kreimer AR, Herrero R; CVT Vaccine Group.

J Natl Cancer Inst. 2014 Dec 5;107(1):400. doi: 10.1093/jnci/dju400. Print 2015 Jan.

2.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

3.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

4.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

5.

Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.

Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2013 Nov 15;208(10):1643-52. doi: 10.1093/infdis/jit369. Epub 2013 Sep 6.

6.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group.

PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. Print 2013.

7.

Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment.

Rodríguez AC, Solomon D, Herrero R, Hildesheim A, González P, Wacholder S, Porras C, Jiménez S, Schiffman M; CVT Group.

Am J Epidemiol. 2013 Sep 1;178(5):752-60. doi: 10.1093/aje/kwt047. Epub 2013 Jul 10.

8.

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica.

Clarke M, Schiffman M, Wacholder S, Rodriguez AC, Hildesheim A, Quint W; Costa Rican Vaccine Trial Group.

BMC Infect Dis. 2013 Jul 8;13:308. doi: 10.1186/1471-2334-13-308.

9.

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.

Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group.

PLoS One. 2013;8(1):e53067. doi: 10.1371/journal.pone.0053067. Epub 2013 Jan 2.

10.

Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.

Castro FA, Quint W, Gonzalez P, Katki HA, Herrero R, van Doorn LJ, Schiffman M, Struijk L, Rodriguez AC, DelVecchio C, Lowy DR, Porras C, Jimenez S, Schiller J, Solomon D, Wacholder S, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2012 Oct 1;206(7):1103-10. Epub 2012 Jul 30.

11.

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.

Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, Porras C, Schussler J, Jiménez S, Sherman ME, Quint W, Schiller JT, Lowy DR, Schiffman M, Hildesheim A; Costa Rica Vaccine Trial Group.

Cancer Discov. 2011 Oct;1(5):408-19. doi: 10.1158/2159-8290.CD-11-0131. Epub 2011 Sep 9.

12.

Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group.

Sex Transm Dis. 2011 Oct;38(10):976-82. doi: 10.1097/OLQ.0b013e31822545c0.

13.

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; CVT Vaccine Group.

J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. doi: 10.1093/jnci/djr319. Epub 2011 Sep 9.

14.

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.

Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group.

Lancet Oncol. 2011 Sep;12(9):862-70. doi: 10.1016/S1470-2045(11)70213-3. Epub 2011 Aug 22. Erratum in: Lancet Oncol. 2011 Nov;12(12):1096.

15.

Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease.

Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, Van Doorn LJ, Porras C, Wacholder S, Gonzalez P, Sherman ME, Herrero R; CVT Group.

J Infect Dis. 2011 Apr 1;203(7):910-20. doi: 10.1093/infdis/jiq139.

16.

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A; Costa Rican Vaccine Trial Group.

J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62. doi: 10.1093/jnci/djq384. Epub 2010 Oct 13.

17.

Determinants of seropositivity among HPV-16/18 DNA positive young women.

Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, Hutchinson M, Jiménez S, Sherman ME, Wacholder S, Solomon D, van Doorn LJ, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A; Costa Rica HPV Vaccine Trial (CVT) Group.

BMC Infect Dis. 2010 Aug 11;10:238. doi: 10.1186/1471-2334-10-238.

18.

Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.

Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Wang SS, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M; Costa Rica HPV Vaccine Trial (CVT) Group.

Sex Transm Dis. 2010 Nov;37(11):706-14. doi: 10.1097/OLQ.0b013e3181e1a2c5.

PMID:
20661178
19.

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials.

Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, Hildesheim A, Rodríguez AC, Solomon D, Herrero R, Schiffman M; CVT group.

BMJ. 2010 Mar 2;340:c712. doi: 10.1136/bmj.c712.

20.

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, González P, Porras C, Jiménez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrisey K, Estrada Y, Cortés B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M; Costa Rica Vaccine Trial (CVT) Group.

Vaccine. 2008 Sep 2;26(37):4795-808. doi: 10.1016/j.vaccine.2008.07.002. Epub 2008 Jul 18.

Supplemental Content

Loading ...
Support Center